Last reviewed · How we verify
high dose TXA
High dose TXA, marketed by Boston Children's Hospital, holds a niche position in the pharmaceutical market with its unique application. The drug benefits from a strong patent protection until 2028, providing a significant barrier to generic competition. However, the lack of detailed revenue figures and clear primary indication data poses a risk in assessing its commercial viability and market impact.
At a glance
| Generic name | high dose TXA |
|---|---|
| Also known as | Tranexamic acid, Cyclokapron, Craniofacial surgery |
| Sponsor | Boston Children's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery (EARLY_PHASE1)
- Dose-Dependent Effects of Intraoperative Tranexamic Acid on Surgical Bleeding and Transfusion Requirements in Multilevel Thoracolumbar Spinal Surgery (NA)
- Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA） (PHASE2)
- Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial (PHASE1)
- Combined IV and Topical TXA in Major Spine Surgery (EARLY_PHASE1)
- Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section (NA)
- Tranexamic Acid Dose and Confusion After Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |